NCT02250456

Brief Summary

Turner syndrome is a genetic condition, rare, due to the total or partial absence of one X chromosome, affecting 1/2500 newborn female. It combines almost constantly short stature and ovarian failure with infertility. Other anomalies are inconstant: morphological characteristics of varying intensity, associated malformations, and increased risk of acquired diseases ... The prognosis of patients reaching the Turner Syndrome is linked to cardiovascular complications (congenital heart disease, dilatation of the ascending aorta with risk of dissection or rupture of aneurysm), causing early mortality with reduction of life expectancy of at least 10 years. For these reasons, screening for heart disease and dilatation of the ascending aorta is established and is intended to prevent the complications associated with medical treatment and / or surgery to increase life expectancy and reduce the co-morbidities. On the vascular level, the recommendations other than those relating to the monitoring of the diameter of the ascending aorta include research of renal artery stenosis by doppler ultrasound if the patient is hypertensive and looking for lymphedema. However, other arterial lesions were described in the literature, outside of the aneurysm of the ascending aorta. These peripheral arterial lesions can also be life and / or functional prognosis of the patient. Ascending aorta dilation seems not to be exclusive in Turner syndrome. In addition, specific vascular lesions outside the affected artery are described: hepatic cirrhosis by vascular depletion, lymphedema and varicose veins. The prevalence of venous or lymphatic disease is unknown. A single-center review of 9 cases of patients followed at the University Hospital of Strasbourg showed the presence of vascular lesions discovered incidentally during assessments performed for reasons other than cardiovascular screening: cystic lymphangioma, internal carotid aneurysm, agenesis of the inferior vena cava, early varicose veins, embryonic cerebral artery, etc ... None of these patients showed any dilatation of the ascending aorta or heart disease. Peripheral vascular abnormalities in this patient group are exclusive. In this study, we seek to demonstrate that arterial disease in Turner syndrome involve the entire arterial territory and is not confined to the ascending aorta. Screening for arterial lesions should be performed on the entire arterial vascular tree and regularly in the course of time, especially as the presence of cardiovascular risk factors increases with the age of these patients. The venous and lymphatic vascular damage in the literature and in our series of cases in University Hospital of Strasbourg description should also lead to the detection of these lesions. These vascular complications can be alone responsible for the reduction in life expectancy or responsible for serious morbidity. Improved screening of associated vascular lesions is necessary to enable the best prevention of cardiovascular complications. It is also to establish the prevalence of vascular anomalies, whether arterial, venous or lymphatic, to better understand the disease and its management. By collecting systematically karyotype leading to diagnosis, it may be possible to make a link between the genetic defect and heart or vascular disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
125

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2013

Longer than P75 for all trials

Geographic Reach
1 country

6 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2013

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

September 23, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 26, 2014

Completed
9.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

June 30, 2022

Status Verified

June 1, 2022

Enrollment Period

11 years

First QC Date

September 23, 2014

Last Update Submit

June 28, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Collection of clinical events and systematized vascular ultrasound explorations

    Reports of annual clinical events and results of complementary cardiovascular investigations. Systematized arterial and venous ultrasound explorations once a year. Reports karyotype used to put the diagnosis of turner Syndrome to perform correlations karyotype - phenotype and karyotype - event. Annual standardized biological exploration.

    Annual evaluation with a 5 years follow-up

Study Arms (1)

Turner syndrome patients and vascular abnormalities

Procedure: Echo doppler

Interventions

Echo dopplerPROCEDURE

vascular ultrasound explorations

Turner syndrome patients and vascular abnormalities

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patient with Turner Syndrome.

You may qualify if:

  • Any woman over 18 years with Turner Syndrome confirmed by karyotype
  • Affiliated to a social security scheme
  • Having signed an informed consent
  • Having been informed of the results of the medical examination prior

You may not qualify if:

  • Inability to give informed patient information related to comprehension difficulties
  • Topic featuring against-indications for MRI examination:
  • pacemaker or automatic defibrillator, implanted pump
  • auditory nerve stimulator, anal nerve stimulator, etc ...
  • the ferromagnetic objects in the soft tissues, intraocular metallic objects, cerebral vascular clips
  • claustrophobia
  • morphotype not allowing access to MRI
  • Patient under judicial protection, guardianship or trusteeship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Service de Chirurgie et Médecine Vasculaire, CHU Jean Minjoz

Besançon, 25030, France

Location

Service d'Angiologie, CHU Bocage

Dijon, 21079, France

Location

Service de gynécologie, Centre Médico Chirurgical Obstétrical, Hôpitaux Universitaires

Schiltigheim, 67303, France

Location

Service d'endocrinologie, Hôpital Civil, Hôpitaux Universitaires

Strasbourg, 67091, France

Location

Service d'explorations fonctionnelles non invasives cardio-vasculaires, Nouvel Hôpital Civil, Hôpitaux Universitaires

Strasbourg, 67091, France

Location

Service HTA, maladies vasculaires et pharmacologie clinique, Nouvel Hôpital Civil, Hôpitaux Universitaires

Strasbourg, 67091, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

MeSH Terms

Conditions

Turner SyndromePeripheral Vascular DiseasesVascular MalformationsLymphedema

Condition Hierarchy (Ancestors)

Gonadal DysgenesisDisorders of Sex DevelopmentUrogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesSex Chromosome Disorders of Sex DevelopmentMale Urogenital DiseasesHeart Defects, CongenitalCardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSex Chromosome DisordersChromosome DisordersGenetic Diseases, InbornGonadal DisordersEndocrine System DiseasesVascular DiseasesLymphatic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Sébastien GAERTNER, MD

    Hôpitaux Universitaires de Strasbourg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2014

First Posted

September 26, 2014

Study Start

July 1, 2013

Primary Completion

July 1, 2024

Study Completion

July 1, 2024

Last Updated

June 30, 2022

Record last verified: 2022-06

Locations